scispace - formally typeset
Journal ArticleDOI

Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Abstract
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...

read more

Citations
More filters
Journal ArticleDOI

HSCT-Based Approaches for Tolerance Induction in Renal Transplant

TL;DR: The preclinical work that has led to the clinical application of the various approaches are discussed and a summary of the most current clinical data from groups throughout the world is discussed.
Journal ArticleDOI

Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.

TL;DR: Differences in cardiovascular risk factors and 1-year GFR highlight the need for further investigation of the optimal utilization of SRL in kidney transplantation, and demonstrate worse patient survival initially with TAC/SRL, with improved outcomes in a later era that were temporally associated with reduced TAC exposure.
Journal ArticleDOI

Azathioprine, UV light, and skin cancer in organ transplant patients—do we have an answer?

TL;DR: As the cumulative dose of immunosuppressive medication escalates, paralleling increasing survival years post-transplantation, a dramatic increase in the prevalence of NMSC is being observed in the ever-growing population of ‘transplant veterans’ worldwide.
Journal ArticleDOI

New developments in immunosuppressive therapy for heart transplantation.

TL;DR: This article gives an overview of the immunosuppressive agents in current use, with a detailed review of emerging drugs with novel therapeutic targets.
Journal ArticleDOI

Monitoring immunosuppression with measures of NFAT decreases cancer incidence

TL;DR: A 67-year-old patient with a history of recurrent non-melanoma skin cancer is presented and NFAT-regulated gene expression measured in peripheral blood allowed us to predict "safe" immunosuppression and patients could maintain a stable allograft function, a breakthrough in transplantation medicine.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI

Risk factors for chronic rejection in renal allograft recipients.

TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)